[Dopa-sensitive dystonia].
Dopa-sensitive dystonia has been recognised for twenty years. It may occur in the first years of life. It first affects the lower limbs, then generalized becomes, as in torsion dystonia. Eight clinical cases are presented in five boys and three girls. The absence of the disorder in the parents, but its presence in siblings in three cases suggests that it might be recessively inherited. The symptoms are severe enough to cause major functional disability. In some cases, the intensity of the motor disorder varies during the days being, less pronounced in the morning or after a nap and more marked in the evening. Nonetheless, this feature is not constant and thus cannot be considered as an essential diagnostic criterion. Treatment with levodopa gives remarkable and durable results, but it must be continued indefinitely. Abnormal movements accompany an overdose but regress when the dosage is decreased. Unlike Parkinson's disease, it is not necessary to increase or fragment doses to avoid fluctuations in the efficacy of treatment during the day. On the contrary, after several years of the illness a decrease in daily dosage sometimes to a single dose is possible. Discontinuing treatment leads to reappearance of dystonia after two or three days. There are no established biological criteria to aid diagnosis. However, a decrease in urine levels of homovanillic acid was observed in two cases. Dopa-sensitive dystonia should be regarded as distinct from juvenile Parkinson's disease, firstly because of its symptomatology and secondly, and more importantly, because of its particular course, since fluctuations in therapeutic efficacy are never observed. It is the only known example of dopaminergic insufficiency that is chronically almost completely controlled by a modest exogenous supply of levodopa.
Rondot
P
P
Hôpital Sainte Anne, Paris.
Aicardi
J
J
Goutières
F
F
Ziegler
M
M
D002230:Carbidopa / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004421:Dystonia / Q000188:drug therapy* / Q000235:genetics; D005260:Female; D005500:Follow-Up Studies; D006719:Homovanillic Acid / Q000652:urine; D006801:Humans; D007223:Infant; D007980:Levodopa / Q000097:blood / Q000627:therapeutic use*; D008297:Male
D007980:Levodopa; D002230:Carbidopa; D006719:Homovanillic Acid
Dystonies dopa-sensibles.